HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
In this podcast, Aditya Bardia from the Massachusetts General Hospital, Harvard Medical School in Boston, and Giuseppe Viale from the Department of Pathology and Laboratory Medicine at the European Institute of Oncology in Milan discuss HER2-low breast cancer, including the implications of the recent US FDA and EU approval of trastuzumab deruxtecan (T-DXd) for use in patients with HER2-low breast cancer, the new challenges that this development presents, and ongoing research that will help refine and define HER2-low patient identification. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast...